Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.

ABSTRACT:

Importance

Hypoglycemia, common in patients with type 1 diabetes, is a major barrier to achieving good glycemic control. Severe hypoglycemia can lead to coma or death.

Objective

To determine whether insulin degludec is noninferior or superior to insulin glargine U100 in reducing the rate of symptomatic hypoglycemic episodes.

Design, setting, and participants

Double-blind, randomized, crossover noninferiority trial involving 501 adults with at least 1 hypoglycemia risk factor treated at 84 US and 6 Polish centers (January 2014-January 12, 2016) for two 32-week treatment periods, each with a 16-week titration and a 16-week maintenance period.

Interventions

Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 2

SUBMITTER: Lane W 

PROVIDER: S-EPMC5817477 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature